Custom Pharma AI Agents & Agentic AI

The pharmaceutical industry generates enormous volumes of regulatory filings, clinical data, safety reports, and commercial intelligence that no human team can fully process manually. Traditional rule-based automation handles the predictable cases but breaks down when workflows require judgment, interpretation of unstructured text, or adaptation to novel situations. Agentic AI fills this gap: autonomous software systems that combine large language model reasoning with structured tool use, enabling them to read documents, query databases, make decisions, and execute multi-step workflows while maintaining full auditability.

IntuitionLabs designs and builds custom AI agents purpose-built for pharmaceutical and life-science organizations, orchestrated through Temporal durable workflow infrastructure with GxP-compliant guardrails and human-in-the-loop approval gates at every regulated decision point.

At the core of every pharmaceutical AI agent is a ReAct loop: the agent receives an observation (new data, a user request, or the result of a previous action), generates a chain-of-thought reasoning trace explaining what it knows and what it needs to do next, selects and executes a tool or action, observes the result, and repeats. This loop continues until the agent determines that its objective is satisfied or that it needs to escalate to a human.

In a pharmacovigilance context, for example, an agent monitoring FDA FAERS data would observe a new batch of adverse event reports, reason about which reports are relevant to its assigned product portfolio, execute queries against the FAERS database to pull detailed case narratives, analyze each case against known product safety profiles, and draft a signal assessment report, iterating through this loop for each relevant report.

Chain-of-thought (CoT) prompting, first formalized by Wei et al. at Google Brain, is the mechanism by which agents produce interpretable reasoning traces before taking actions. In regulated pharmaceutical environments, these reasoning traces serve a dual purpose: they improve the accuracy of complex multi-step tasks by forcing the model to decompose problems, and they provide the auditable decision trail that regulators expect.

When a regulatory intelligence agent determines that a new EMA scientific guideline impacts your product strategy, the chain-of-thought trace shows exactly which sections of the guideline were analyzed, what comparisons were made to current filings, and why the agent reached its conclusion. This transparency is not optional in pharma; it is a prerequisite for regulatory acceptance.

Effective agents require memory at multiple time scales. Short-term memory, often called the agent scratchpad or working memory, holds the context accumulated during a single task execution: retrieved documents, intermediate calculations, and prior reasoning steps. This memory is bounded by the LLM context window but can be managed through summarization and selective retrieval to handle tasks that span thousands of documents.

Long-term memory persists across agent runs and enables agents to learn from past interactions: which document sources proved most useful for a given query type, which formatting patterns were preferred by human reviewers, or which regulatory topics have been trending over time. We implement long-term memory through vector databases that store embeddings of past agent interactions, indexed by topic, outcome, and quality score. This allows agents to retrieve relevant past experiences when encountering similar tasks, improving accuracy and consistency over time. The generative agent architecture research from Stanford provides the theoretical foundation for these memory systems.

Selecting optimal clinical trial sites is one of the most consequential decisions in drug development, directly impacting enrollment timelines, data quality, and trial costs. Our site selection agent synthesizes data from multiple sources to produce ranked site recommendations with full transparency into the scoring methodology.

The workflow begins when a clinical operations team provides the agent with protocol parameters: indication, inclusion/exclusion criteria, target enrollment numbers, geographic preferences, and timeline constraints. The agent then queries ClinicalTrials.gov to identify investigators with relevant trial experience, analyzing enrollment rates, completion rates, and protocol deviation histories. It cross-references investigator publication records in PubMed to assess therapeutic area expertise. It evaluates site infrastructure by analyzing historical trial conduct data, available from public registries, and integrating any proprietary site intelligence your organization has accumulated. Patient population analysis uses epidemiological data and geographic demographic information to estimate the accessible patient pool near each candidate site. The agent produces a ranked list of recommended sites with detailed scorecards explaining each recommendation, including historical enrollment velocity, investigator expertise score, infrastructure assessment, and patient pool estimate. This output is designed for human review by the clinical operations team, who make the final site selection decisions informed by the agent analysis, following ICH E8(R1) principles for clinical trial design.

Intellectual property strategy is a strategic pillar of pharmaceutical business development, and the patent landscape in any therapeutic area is complex and constantly shifting. Our patent landscape agent automates the continuous monitoring and analysis of patent filings, grants, expirations, and challenges across global patent offices.

The agent regularly scans patent databases for new filings and status changes relevant to configured therapeutic areas and molecular targets. It parses patent claims using specialized NLP to extract key information: compound structures, method-of-use claims, formulation patents, and process patents. For each relevant patent, the agent maps it to the competitive landscape, identifying which products and companies are affected. It tracks Orange Book patent listings for small molecules and Purple Book exclusivity data for biologics, identifying upcoming patent cliffs and Paragraph IV challenge opportunities. The agent generates periodic landscape reports that visualize patent coverage across time, showing windows of opportunity for generic or biosimilar entry. For business development teams, it identifies licensing opportunities by finding patents with broad claims that are underutilized or patents nearing expiration that could unlock new formulation strategies. All analyses are accompanied by confidence scores and source citations, enabling patent attorneys to quickly validate the agent findings and focus their expertise on strategic interpretation rather than data gathering.

Risk Evaluation and Mitigation Strategies impose significant operational burdens on pharmaceutical manufacturers: patient enrollment tracking, prescriber certification verification, pharmacy certification, periodic assessment reporting, and ongoing compliance monitoring. Our REMS management agent automates the operational compliance aspects of these programs while maintaining the human oversight required for patient safety decisions.

The agent tracks patient enrollment and re-enrollment across REMS-certified pharmacies, flagging overdue verifications and generating reminder communications. It verifies prescriber certification status and alerts program administrators when certifications approach expiration. For REMS programs requiring laboratory monitoring, the agent tracks required test results and flags missing or overdue assessments. Periodically, the agent compiles assessment data into draft REMS assessment reports following FDA-specified formats, pulling metrics on program enrollment, compliance rates, adverse event data from FAERS, and program effectiveness measures. The draft report is routed through a human review workflow before submission. The agent also monitors FDA communications about REMS modifications, ensuring your program adapts promptly to evolving requirements. By automating the data collection, tracking, and reporting aspects of REMS management, the agent allows your drug safety team to focus on the clinical and scientific judgment that requires human expertise.

The quality and accessibility of data is the single largest determinant of AI agent effectiveness. Pharmaceutical organizations possess vast amounts of valuable data, but it is typically fragmented across dozens of siloed systems, stored in incompatible formats, and governed by complex access control policies. Building effective AI agents requires a deliberate data architecture that makes the right data available to the right agent at the right time, with appropriate security and audit controls.

RAG performance in pharmaceutical document retrieval depends critically on the quality of the embedding model, the chunking strategy, and the retrieval algorithm. We build vector databases using domain-optimized embedding models that understand pharmaceutical terminology, with chunking strategies tailored to document type: section-level chunking for regulatory documents, paragraph-level for SOPs, and abstract-plus-methods chunking for scientific literature. Hybrid retrieval that combines dense vector search with sparse keyword matching (BM25) consistently outperforms either approach alone on pharmaceutical document retrieval benchmarks.

For organizations with mature data infrastructure, we integrate agents with existing data lakes and warehouses rather than building parallel data stores. ETL pipelines feed cleaned, harmonized data into the agent data layer on configurable schedules, ensuring agents operate on current data without requiring real-time access to transactional source systems.

This decoupling protects source systems from agent query load and provides a natural point for data quality validation before agents consume the data. For real-time use cases such as safety signal monitoring or supply chain alerts, we implement change-data-capture patterns that stream updates from source systems to the agent data layer with minimal latency. The data architecture also includes a metadata catalog that agents can query to discover available data sources, understand data lineage, and assess data freshness, enabling agents to make informed decisions about which data sources to trust for a given analysis.

Approval gates are implemented as Temporal signals that pause workflow execution until a designated human approver reviews and approves or rejects the agent output. The approval interface presents the agent reasoning trace, output, supporting evidence, and confidence score, enabling the reviewer to make an informed decision quickly. Rejected outputs include a feedback mechanism where the reviewer can specify what was wrong, which is fed back to the agent for revision.

Escalation workflows handle cases where the designated reviewer is unavailable: after a configurable timeout, the approval request escalates to a backup reviewer or manager. For time-sensitive workflows such as safety signal assessment, escalation timers can be set to minutes rather than hours. The approval workflow also supports multi-level review for high-risk outputs, requiring approval from both a subject matter expert and a quality reviewer before the agent proceeds.

Every human interaction with agent output generates training signal that can improve future performance. When reviewers approve, reject, or edit agent outputs, these decisions are captured as feedback data. Approved outputs confirm that the agent approach was correct. Rejected outputs with reviewer comments identify failure modes that prompt engineering or fine-tuning can address. Edited outputs provide the most granular signal, showing exactly where the agent reasoning or generation diverged from expert expectations.

We aggregate this feedback data and periodically retrain or refine agent components: updating prompts to address common error patterns, fine-tuning classification models on new labeled examples, and adjusting retrieval parameters to surface more relevant source documents. This creates a virtuous cycle where agents improve continuously through normal operational use, reducing the human review burden over time while maintaining quality standards.

Our delivery methodology follows an iterative approach designed for regulated environments. Week one to two focuses on domain discovery: understanding your data landscape, regulatory requirements, existing workflows, and success criteria. Week three to four delivers a working prototype agent operating on a representative data subset. Weeks five through eight involve iterative refinement based on domain expert feedback, integration with production data sources, and security hardening. Weeks nine through twelve cover validation documentation, user training, production deployment, and monitoring setup. Throughout this process, we follow risk-based validation principles to ensure regulatory compliance without unnecessary overhead.

Most organizations begin with a single focused agent addressing a specific pain point: regulatory intelligence monitoring, literature screening, or adverse event triage. As confidence grows and the organization builds operational experience, additional agents are added to address adjacent workflows. Eventually, agents begin to collaborate: a regulatory intelligence agent detects a guideline change, triggers a labeling review agent, which in turn triggers a promotional material review agent. This evolution from isolated agents to interconnected agentic systems happens incrementally, with each new agent building on the infrastructure, governance, and organizational learning established by its predecessors.